Key Findings:
- In a cohort of 1856 high grade gliomas, 181 (9.8%) displayed mutations in chromatin remodeling genes.
- High grade gliomas with these mutations had lower expression of immune-related genes and a colder tumor microenvironment.
- Patients with high grade gliomas with chromatin remodeling gene mutations had a longer overall survival when treated with temozolomide versus patients without these mutations (33 months versus 22 months, HR: 0.713, 95% CI: 0.581-0.876).